This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Charles River Associates (CRA) Expands Global Life Sciences Offering

Charles River Associates (NASDAQ: CRAI), a worldwide leader in providing management, economic, and financial consulting services, today announced that Mark Beards has joined the firm as a vice president in the Life Sciences Practice based in London. Mr. Beards most recently led European healthcare equity research at Goldman Sachs in London. Prior to that, he was a consultant at McKinsey & Company and worked in commercial and research roles at leading, global pharmaceutical companies.

“Mark Beards’ expansive background—as an equity analyst in capital markets covering European life sciences companies, a strategy consultant advising large cap pharmaceutical organizations, and a business manager with direct sector experience—makes him a valuable addition to CRA,” said CRA's President and Chief Executive Officer Paul Maleh. “His deep knowledge base and practical approach allow for advising and problem-solving on a range of issues confronting life sciences companies. It is a pleasure to welcome him to CRA, where he will play an important role within our global life sciences offering.”

Mr. Beards has 20 years of experience in the life sciences and financial sectors. His specialties include commercialization, R&D, licensing, and setting corporate and product strategy. He has transformed underperforming business units into highly successful ones; developed licensing strategies to direct business development priorities; led due diligence, negotiations, and deal structures for licensing agreements; constructed go-to market strategies; and redesigned global marketing functions.

In his most recent role at Goldman Sachs, Mr. Beards was Vice President, Head of Equity Research, European Healthcare, and was responsible for coverage of the pharmaceutical, medical technology, and biotechnology sectors. He was the primary analyst on diversified pharmaceutical companies with a combined market capitalization of $335 billion. At McKinsey & Company, he focused on life sciences and advised global pharmaceutical companies in such areas as corporate strategy development, corporate transformation, product launch strategy, distribution valuation, consumer segmentation, and brand positioning. Prior to this role, Mr. Beards spent 11 years in business development and commercial strategy roles at Abbott Laboratories and GlaxoSmithKline, respectively. He began his career as an accountant and is a Chartered Management Accountant, ACMA. He holds a Diploma in Business Management from Henley Management College and a BA (Hons) degree and an MA degree in Mathematics from The Queen’s College, Oxford.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.98 -0.21%
FB $116.77 -0.56%
GOOG $692.36 0.00%
TSLA $230.00 -1.00%
YHOO $36.01 0.00%


Chart of I:DJI
DOW 17,750.91 -140.25 -0.78%
S&P 500 2,063.37 -18.06 -0.87%
NASDAQ 4,763.2240 -54.37 -1.13%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs